[ACT]IVATED AML Resource Guide III
Download Resource Guide Download Resource Guide See More from [ACT]IVATED AML Share Your Feedback About [ACT]IVATED AML
What Are Potential Impacts of Artificial Intelligence on AML Patient Care?
https://vimeo.com/948960199 How might acute myeloid leukemia (AML) patient care be impacted by artificial intelligence? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School shares his perspective on potential risks…
What Is the Role of Bone Marrow Biopsies in AML Treatment?
https://vimeo.com/948960276 What part do bone marrow biopsies play in acute myeloid leukemia (AML) treatment? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses the value and information gained…
Why Is Shared Decision-Making Important for AML Patients?
https://vimeo.com/948960301 What makes shared decision-making vital for acute myeloid leukemia (AML) patients? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses his approach to shared decision-making, the roles…
Do AML Bone Marrow Biopsies Show Racial and Ethnic Variances?
https://vimeo.com/948960333 Are racial and ethnic differences shown in acute myeloid leukemia (AML) bone marrow biopsies? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses what early AML studies…
How Bone Marrow Biopsies Impact Acute Myeloid Leukemia Treatment and Care
https://vimeo.com/948960365 How are acute myeloid leukemia (AML) treatment and care impacted by bone marrow biopsies? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School explains the role that bone…
Novel AML Therapy Use | Impact of Socioeconomic Status and Other Factors
https://vimeo.com/948960382 How do socioeconomic status and other factors impact novel acute myeloid leukemia (AML) therapy use? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses major factors that…
Underrepresented AML Clinical Trial Groups | What Solutions Are Underway?
https://vimeo.com/948960402 What steps are being taken to help underrepresented acute myeloid leukemia (AML) clinical trial groups? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses an important approach…
Why Is Post-Access Enrollment Vital in AML Clinical Trial Participation?
https://vimeo.com/948960428 For acute myeloid leukemia (AML) clinical trial participation, what makes post-access enrollment essential? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that play into post-access…
What AML Clinical Trial Inequities Do Minority and Ethnic Groups Face?
https://vimeo.com/948960457 Do minority and ethnic groups face acute myeloid leukemia (AML) clinical trial inequities? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses research study results of NCI-designated…
What Are Key Acute Myeloid Leukemia Care Barriers and Solutions?
https://vimeo.com/948960484 What are key barriers and solutions to acute myeloid leukemia (AML) care? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that create AML care barriers,…
[ACT]IVATED AML Resource Guide II
Download Resource Guide Download Resource Guide See More from [ACT]IVATED AML Share Your Feedback About [ACT]IVATED AML